Literature DB >> 25320539

Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment.

Cristina Sánchez-Montes1, Vicente Ortiz1, Guillermo Bastida1, Ester Rodríguez1, María Yago1, Belén Beltrán1, Mariam Aguas1, Marisa Iborra1, Vicente Garrigues1, Julio Ponce1, Pilar Nos1.   

Abstract

AIM: To investigate the influence of thiopurines and biological drugs on the presence of small intestinal bacterial overgrowth (SIBO) in patients with inactive Crohn's disease (CD).
METHODS: This was a prospective study in patients with CD in remission and without corticosteroid treatment, included consecutively from 2004 to 2010. SIBO was investigated using the hydrogen glucose breath test.
RESULTS: One hundred and seven patients with CD in remission were included. Almost 58% of patients used maintenance immunosuppressant therapy and 19.6% used biological therapy. The prevalence of SIBO was 16.8%. No association was observed between SIBO and the use of thiopurine Immunosuppressant (12/62 patients), administration of biological drugs (2/21 patients), or with double treatment with an anti-tumor necrosis factor drugs plus thiopurine (1/13 patients). Half of the patients had symptoms that were suggestive of SIBO, though meteorism was the only symptom that was significantly associated with the presence of SIBO on univariate analysis (P < 0.05). Multivariate analysis revealed that the presence of meteorism and a fistulizing pattern were associated with the presence of SIBO (P < 0.05).
CONCLUSION: Immunosuppressants and/or biological drugs do not induce SIBO in inactive CD. Fistulizing disease pattern and meteorism are associated with SIBO.

Entities:  

Keywords:  Bacterial overgrowth; Biologics; Crohn’s disease; Inflammatory bowel disease; Thiopurines

Mesh:

Substances:

Year:  2014        PMID: 25320539      PMCID: PMC4194585          DOI: 10.3748/wjg.v20.i38.13999

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease.

Authors:  Daniel Mishkin; Francis M Boston; David Blank; Morty Yalovsky; Seymour Mishkin
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  Safety of infliximab and other biologic agents in the inflammatory bowel diseases.

Authors:  Jagadeshwar G Reddy; Edward V Loftus
Journal:  Gastroenterol Clin North Am       Date:  2006-12       Impact factor: 3.806

4.  Comparison of the 1-gram (14)C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth.

Authors:  P O Stotzer; A F Kilander
Journal:  Digestion       Date:  2000       Impact factor: 3.216

5.  Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease.

Authors:  P Rutgeerts; Y Ghoos; G Vantrappen; H Eyssen
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

Review 6.  Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.

Authors:  Wai-Kit Lo; Walter W Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2012-12-24       Impact factor: 11.382

Review 7.  Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation.

Authors:  Joseph Romagnuolo; Dan Schiller; Robert J Bailey
Journal:  Am J Gastroenterol       Date:  2002-05       Impact factor: 10.864

8.  Breath hydrogen testing in bacterial overgrowth of the small intestine.

Authors:  P Kerlin; L Wong
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

9.  Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth.

Authors:  C E King; P P Toskes
Journal:  Gastroenterology       Date:  1986-12       Impact factor: 22.682

Review 10.  Small bowel bacterial overgrowth: presentation, diagnosis, and treatment.

Authors:  Virmeet V Singh; Phillip P Toskes
Journal:  Curr Gastroenterol Rep       Date:  2003-10
View more
  10 in total

Review 1.  AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Authors:  Jean-Frederic Colombel; Andrea Shin; Peter R Gibson
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

Review 2.  Gastroduodenal "Dysbiosis": a New Clinical Entity.

Authors:  Ayesha Shah; Mark Morrison; Gerald J Holtmann
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Small intestinal bacterial overgrowth in inflammatory bowel disease.

Authors:  Ayesha Shah; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2022-01-15

4.  Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Zaid Tafesh; Elliot Coburn; Russell Weg; Neena Malik; Colleen Webb; Hoda Hammad; Ellen Scherl; Brian P Bosworth
Journal:  Dig Dis Sci       Date:  2018-05-14       Impact factor: 3.199

Review 5.  Role of antibiotics for treatment of inflammatory bowel disease.

Authors:  Orna Nitzan; Mazen Elias; Avi Peretz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study.

Authors:  Thorsten Brechmann; Andre Sperlbaum; Wolff Schmiegel
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

7.  Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections?

Authors:  M Andrei; T Nicolaie; A Stoicescu; A Teiușanu; Ș Gologan; M Diculescu
Journal:  Curr Health Sci J       Date:  2015-01-29

8.  Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel.

Authors:  Ahmed Dawood Mohammed; Zahraa Mohammed; Mary M Roland; Ioulia Chatzistamou; Amy Jolly; Lillian M Schoettmer; Mireya Arroyo; Khadija Kakar; Yuan Tian; Andrew Patterson; Mitzi Nagarkatti; Prakash Nagarkatti; Jason L Kubinak
Journal:  Nat Commun       Date:  2022-01-26       Impact factor: 17.694

9.  Small intestinal bacterial overgrowth is associated with clinical relapse in patients with quiescent Crohn's disease: a retrospective cohort study.

Authors:  Juan Wei; Jing Feng; Ji Xuan; Fangyu Wang; Liya Chen; Zhao Yang; Hui Tao; Liuying Li
Journal:  Ann Transl Med       Date:  2022-07

10.  Association between small intestinal bacterial overgrowth and beta-cell function of type 2 diabetes.

Authors:  Li-Hui Yan; Biao Mu; Da Pan; Ya-Nan Shi; Ji-Hong Yuan; Yue Guan; Wang Li; Xiao-Yi Zhu; Lei Guo
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.